James Atkinson - Viveve Medical Chief Business Officer and President
| VIVEDelisted Stock | USD 0.1 0.0005 0.53% |
President
Mr. James G. Atkinson is Chief Business Officer and President of Viveve Medical, Inc. He was appointed to serve as the Chief Business Officer and President of the Company and Viveve, Inc., a wholly owned subsidiary of Viveve Medical, Inc., effective as of February 4, 2015. Mr. Atkinson has over 30 years of experience in medical device sales, marketing and business development with both Fortune 50 and startup medical device companies. Mr. Atkinson was a founding principal at Ulthera, Inc. where he served as Senior Vice President of Sales and Marketing from October 2006 through April 2014. While at Ulthera, he assisted in growing the company from 3 to 165 employees and established a global distribution network that included 42 distributors, covering 52 countries. Mr. Atkinsons prior experience includes various executive positions, including Vice President of Sales and Marketing for the Cardiac Surgery Division at St. Jude Medical, Inc. from October 2004 to October 2006 where his responsibilities included launching the Biocor stented tissue valve, recognized as the fastest growing heart valve brand in the industry, Vice President of Sales for Medtronic Vascular, a 200 million division of Medtronic, Inc., a company whose stock is traded on the New York Stock Exchange, from January 2003 to September 2004 and cofounder and Vice President of Sales and Business Development for Medical Simulation Corporationrationration. Mr. Atkinsons career began as a sales representative at Ethicon Endosurgery, a Johnson Johnson company, where he progressed through positions with increasing responsibility to Regional Manager. since 2015.
| Age | 59 |
| Tenure | 9 years |
| Phone | 720 696 8100 |
| Web | https://www.viveve.com |
Viveve Medical Management Efficiency
The company has return on total asset (ROA) of (0.6213) % which means that it has lost $0.6213 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1099) %, meaning that it created substantial loss on money invested by shareholders. Viveve Medical's management efficiency ratios could be used to measure how well Viveve Medical manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 5.12 M in liabilities with Debt to Equity (D/E) ratio of 1.12, which is about average as compared to similar companies. Viveve Medical has a current ratio of 1.29, suggesting that it may not have the ability to pay its financial obligations when due. Debt can assist Viveve Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Viveve Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Viveve Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Viveve to invest in growth at high rates of return. When we think about Viveve Medical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | PRESIDENT Age | ||
| Paul Hickey | ReShape Lifesciences | 59 | |
| Francis Capitanio | Biomerica | 73 | |
| Peter Delange | ReShape Lifesciences | 47 | |
| Andrew Lukowiak | Talis Biomedical Corp | 51 | |
| Naqeeb Ansari | ReShape Lifesciences | 63 | |
| Jeffrey Kapner | Rapid Micro Biosystems | 46 | |
| Vincent MS | Cytosorbents Crp | 66 | |
| Jona Zumeris | NanoVibronix | 62 | |
| Kevin Condrin | ReShape Lifesciences | N/A | |
Management Performance
| Return On Equity | -2.11 | ||||
| Return On Asset | -0.62 |
Viveve Medical Leadership Team
Elected by the shareholders, the Viveve Medical's board of directors comprises two types of representatives: Viveve Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viveve. The board's role is to monitor Viveve Medical's management team and ensure that shareholders' interests are well served. Viveve Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viveve Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jim Robbins, Principal Financial Officer | ||
| Martin PE, Dev Research | ||
| Suzon Lommel, VP Affairs | ||
| Debora Jorn, Director | ||
| Scott Durbin, CEO Director | ||
| Lori Bush, Director | ||
| Jon Plexico, Director | ||
| Brigitte Smith, Chairman of the Board | ||
| Karen Zaderej, Director | ||
| James Atkinson, Chief Business Officer and President | ||
| Steven Basta, Director | ||
| Lori McMillan, VP HR | ||
| Daniel Janney, Independent Director | ||
| Deborah MBA, Advisor Director | ||
| Jeannie Swindle, Sr Communications | ||
| Patricia Scheller, CEO, Director | ||
| Alan Curtis, Vice President - Regulatory, Clinical and Quality | ||
| Gary Kaiser, VP Marketing | ||
| Arlene Morris, Director | ||
| Steve Lopez, Director - Operations | ||
| Jeff Sinclair, VP Sales |
Viveve Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Viveve Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.11 | ||||
| Return On Asset | -0.62 | ||||
| Operating Margin | (3.10) % | ||||
| Current Valuation | 4.26 M | ||||
| Shares Outstanding | 10.72 M | ||||
| Shares Owned By Institutions | 5.21 % | ||||
| Number Of Shares Shorted | 374.24 K | ||||
| Price To Earning | (2.59) X | ||||
| Price To Book | 3.62 X | ||||
| Price To Sales | 0.66 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Viveve Pink Sheet
If you are still planning to invest in Viveve Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viveve Medical's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Directory Find actively traded commodities issued by global exchanges |